The New York City-based ophthalmology research and development company announced on Tuesday that it reached an agreement with the FDA regarding the design of its first Phase 3 trial for the drug.
Ohr's treatment, known as Squalamine, treats neovascular age-related macular degeneration (AMD). AMD is a condition that can cause eye swelling and damage, according to the National Institutes of Health.
"The initiation of our Phase III clinical program is a monumental achievement for the company and represents an important step in our mission to develop and commercialize therapeutics for unmet medical needs in ophthalmology," CEO Jason Slakter said in a statement.
So far today, 1.26 million shares of Ohr have traded, well above the company's 30-day trading average of about 207,000 shares.